DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dive into DelveInsight’s comprehensive report today! @ Small Lymphocytic Lymphoma Pipeline Outlook
Key Takeaways from the Small Lymphocytic Lymphoma Pipeline Report
- On December 05, Dana-Farber Cancer Institute conducted a study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- On December 04, Eli Lilly and Company announced a Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
- DelveInsight’s Small Lymphocytic Lymphoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
- The leading Small Lymphocytic Lymphoma Companies such as Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
- Promising Small Lymphocytic Lymphoma Pipeline Therapies such as Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Small Lymphocytic Lymphoma Treatment Drugs
Small Lymphocytic Lymphoma Overview
SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood. SLL that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).
Small Lymphocytic Lymphoma Emerging Drugs Profile
- TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
- LOXO-305: Loxo Oncology
Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. Pirtobrutinib is currently being studied in multiple clinical trials. Safety and efficacy have not been established for the uses being studied.
- IOV 2001: Iovance Biotherapeutics
IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
The Small Lymphocytic Lymphoma Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Small Lymphocytic Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Lymphocytic Lymphoma Treatment.
- Small Lymphocytic Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Small Lymphocytic Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Lymphocytic Lymphoma market
Explore groundbreaking therapies and clinical trials in the Small Lymphocytic Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New Small Lymphocytic Lymphoma Drugs
Small Lymphocytic Lymphoma Companies
Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others.
Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Small Lymphocytic Lymphoma Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn about new Small Lymphocytic Lymphoma Marketed and Drugs Developments, and key companies with DelveInsight’s expert analysis @ Small Lymphocytic Lymphoma Market Drivers and Barriers
Scope of the Small Lymphocytic Lymphoma Pipeline Report
- Coverage- Global
- Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
- Small Lymphocytic Lymphoma Pipeline Therapies- Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.
- Small Lymphocytic Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Small Lymphocytic Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight’s in-depth pipeline report today! @ Small Lymphocytic Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Small Lymphocytic Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Drug Name : Company Name
- Drug profiles in the detailed report…..
- Last Stage Products (Phase III)
- LOXO-305: Loxo Oncology
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Small Lymphocytic Lymphoma Key Companies
- Small Lymphocytic Lymphoma Key Products
- Small Lymphocytic Lymphoma – Unmet Needs
- Small Lymphocytic Lymphoma – Market Drivers and Barriers
- Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
- Small Lymphocytic Lymphoma Analyst Views
- Small Lymphocytic Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-pipeline-insight